These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11597405)

  • 21. Computational Analysis of CRTh2 receptor antagonist: A Ligand-based CoMFA and CoMSIA approach.
    Babu S; Sohn H; Madhavan T
    Comput Biol Chem; 2015 Jun; 56():109-21. PubMed ID: 25935115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel potent 5-HT(3) receptor ligands based on the pyrrolidone structure: synthesis, biological evaluation, and computational rationalization of the ligand-receptor interaction modalities.
    Cappelli A; Anzini M; Vomero S; Mennuni L; Makovec F; Doucet E; Hamon M; Menziani MC; De Benedetti PG; Giorgi G; Ghelardini C; Collina S
    Bioorg Med Chem; 2002 Mar; 10(3):779-801. PubMed ID: 11814868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of some benzimidazole derivatives with trichomonicidal activity.
    Pérez-Villanueva J; Medina-Franco JL; Caulfield TR; Hernández-Campos A; Hernández-Luis F; Yépez-Mulia L; Castillo R
    Eur J Med Chem; 2011 Aug; 46(8):3499-508. PubMed ID: 21621311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Three-dimensional quantitative structure-activity relationships of 5-HT receptor binding data for tetrahydropyridinylindole derivatives: a comparison of the Hansch and CoMFA methods.
    Agarwal A; Pearson PP; Taylor EW; Li HB; Dahlgren T; Herslöf M; Yang Y; Lambert G; Nelson DL; Regan JW
    J Med Chem; 1993 Dec; 36(25):4006-14. PubMed ID: 8258822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. QSAR studies on piperazinylalkylisoxazole analogues selectively acting on dopamine D3 receptor by HQSAR and CoMFA.
    Cha MY; Lee IY; Cha JH; Choi KI; Cho YS; Koh HY; Pae AN
    Bioorg Med Chem; 2003 Apr; 11(7):1293-8. PubMed ID: 12628656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quinolizidinyl derivatives of 2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxylic acid and 1-homolupinanoyl benzimidazolones as ligands for 5-HT3 and 5-HT4 receptors.
    Sparatore A; Cagnotto A; Sparatore F
    Farmaco; 1999 Apr; 54(4):248-54. PubMed ID: 10384719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular modeling of some 1H-benzimidazole derivatives with biological activity against Entamoeba histolytica: a comparative molecular field analysis study.
    López-Vallejo F; Medina-Franco JL; Hernández-Campos A; Rodríguez-Morales S; Yépez L; Cedillo R; Castillo R
    Bioorg Med Chem; 2007 Jan; 15(2):1117-26. PubMed ID: 17074492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular modeling studies on benzimidazole carboxamide derivatives as PARP-1 inhibitors using 3D-QSAR and docking.
    Zeng H; Zhang H; Jang F; Zhao L; Zhang J
    Chem Biol Drug Des; 2011 Sep; 78(3):333-52. PubMed ID: 21585709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis, binding properties and receptor docking of 4-halo-6-[2-(4-arylpiperazin-1-yl)ethyl]-1H-benzimidazoles, mixed ligands of D2 and 5-HT1A receptors.
    Andrić D; Roglić G; Sukalović V; Soskić V; Kostić-Rajacić S
    Eur J Med Chem; 2008 Aug; 43(8):1696-705. PubMed ID: 18006194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CoMFA and CoMSIA analyses on 1,2,3,4-tetrahydropyrrolo[3,4-b]indole and benzimidazole derivatives as selective CB2 receptor agonists.
    Cichero E; Cesarini S; Mosti L; Fossa P
    J Mol Model; 2010 Sep; 16(9):1481-98. PubMed ID: 20174844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluation.
    Orjales A; Mosquera R; Labeaga L; Rodes R
    J Med Chem; 1997 Feb; 40(4):586-93. PubMed ID: 9046349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, binding and docking-based 3D-QSAR studies of 2-pyridylbenzimidazoles--a new family of high affinity CB1 cannabinoid ligands.
    Mella-Raipán JA; Lagos CF; Recabarren-Gajardo G; Espinosa-Bustos C; Romero-Parra J; Pessoa-Mahana H; Iturriaga-Vásquez P; Pessoa-Mahana CD
    Molecules; 2013 Apr; 18(4):3972-4001. PubMed ID: 23558540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New benzimidazole derivatives: selective and orally active 5-HT3 receptor antagonists.
    Pascual D; Girón R; Alsasua A; Benhamú B; López-Rodríguez ML; Martín MI
    Eur J Pharmacol; 2003 Feb; 462(1-3):99-107. PubMed ID: 12591101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular design based on 3D-pharmacophore. Application to 5-HT4 receptor.
    Bureau R; Daveu C; Lemaître S; Dauphin F; Landelle H; Lancelot JC; Rault S
    J Chem Inf Comput Sci; 2002; 42(4):962-7. PubMed ID: 12132898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benzimidazolone derivatives act as 5-HT4 receptor ligands in rat oesophagus.
    Baxter GS; Clarke DE
    Eur J Pharmacol; 1992 Mar; 212(2-3):225-9. PubMed ID: 1601064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benzimidazolone-based serotonin 5-HT1A or 5-HT7R ligands: synthesis and biological evaluation.
    Badarau E; Suzenet F; Bojarski AJ; Fînaru AL; Guillaumet G
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1600-3. PubMed ID: 19237285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A combination of 3D-QSAR, molecular docking and molecular dynamics simulation studies of benzimidazole-quinolinone derivatives as iNOS inhibitors.
    Zhang H; Zan J; Yu G; Jiang M; Liu P
    Int J Mol Sci; 2012; 13(9):11210-11227. PubMed ID: 23109848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 5-HT(3)R binding of lerisetron: an interdisciplinary approach to drug-Receptor interactions.
    Parihar HS; Suryanarayanan A; Ma C; Joshi P; Venkataraman P; Schulte MK; Kirschbaum KS
    Bioorg Med Chem Lett; 2001 Aug; 11(16):2133-6. PubMed ID: 11514154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and characterization of the first fluorescent antagonists for human 5-HT4 receptors.
    Berque-Bestel I; Soulier JL; Giner M; Rivail L; Langlois M; Sicsic S
    J Med Chem; 2003 Jun; 46(13):2606-20. PubMed ID: 12801225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological evaluation of halogenated and non-halogenated arylpiperazin-1-yl-ethyl-benzimidazoles as D(2) and 5-HT(2A) receptor ligands.
    Tomić M; Vasković D; Tovilović G; Andrić D; Penjišević J; Kostić-Rajačić S
    Arch Pharm (Weinheim); 2011 May; 344(5):287-91. PubMed ID: 21509803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.